Induction of the Epithelial-to-Mesenchymal Transition of Human Colorectal Cancer by Human TNF-β (Lymphotoxin) and its Reversal by Resveratrol.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
26 Mar 2019
Historique:
received: 26 02 2019
revised: 19 03 2019
accepted: 21 03 2019
entrez: 29 3 2019
pubmed: 29 3 2019
medline: 9 8 2019
Statut: epublish

Résumé

Tumor necrosis factor-beta (TNF-β), as an inflammatory mediator that has been shown to promote tumorigenesis, induces NF-κB. Natural multi-targeted agent resveratrol in turn shows anti-inflammatory and anti-cancer properties. Epithelial-to-mesenchymal transition (EMT) allows cancer cells to turn into a motile state with invasive capacities and is associated with metastasis and development of cancer stem cells (CSC). However, TNF-β-induced EMT and the anti-invasion mechanism of resveratrol on CRC are not yet completely understood. We investigated the underlying molecular mechanisms of resveratrol on TNF-β/TNF-βR-induced EMT and migration of CRC cells (HCT116, RKO, SW480) in monolayer or 3D alginate cultures. TNF-β, similar to TNF-α, induced significant cell proliferation, morphological change, from an epithelial to a spindle-like mesenchymal shape with the formation of filopodia and lamellipodia associated with the expression of EMT parameters (elevated vimentin and slug, reduced E-cadherin), increased migration/invasion, and formation of CSC in all CRC cells. Interestingly, these effects were dramatically decreased in the presence of resveratrol or anti-TNF-βR with TNF-β co-treatment, inducing biochemical changes to the mesenchymal-epithelial transition (MET), with a planar cell surface and suppressed formation of CSC cells. This was associated with a significant increase in apoptosis. Furthermore, we found that resveratrol suppressed TNF-β-induced NF-κB and NF-κB-regulated gene biomarkers associated with growth, proliferation, and invasion. Finally, TNF-βR interacts directly with focal adhesion kinase (FAK) and NF-κB. These results suggest that resveratrol down-regulates TNF-β/TNF-βR-induced EMT, at least in part via specific suppression of NF-κΒ and FAK in CRC cells.

Identifiants

pubmed: 30917533
pii: nu11030704
doi: 10.3390/nu11030704
pmc: PMC6471988
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Lymphotoxin-alpha 0
NF-kappa B 0
Receptors, Tumor Necrosis Factor 0
Focal Adhesion Kinase 1 EC 2.7.10.2
PTK2 protein, human EC 2.7.10.2
Resveratrol Q369O8926L

Types de publication

Journal Article

Langues

eng

Références

Prog Biophys Mol Biol. 1999;71(3-4):435-78
pubmed: 10354709
Mol Cell Biol. 1999 Aug;19(8):5785-99
pubmed: 10409765
Nat Rev Mol Cell Biol. 2000 Nov;1(2):91-100
pubmed: 11253370
Eur Cytokine Netw. 2001 Mar;12(1):87-96
pubmed: 11282551
Semin Cancer Biol. 2001 Apr;11(2):119-28
pubmed: 11322831
FEBS Lett. 2001 Jun 15;499(1-2):176-81
pubmed: 11418135
Trends Cell Biol. 2002 Mar;12(3):112-20
pubmed: 11859023
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
Immunity. 2002 Oct;17(4):525-35
pubmed: 12387745
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
J Biol Chem. 2003 Apr 4;278(14):12006-12
pubmed: 12556537
Curr Med Chem Anticancer Agents. 2003 Mar;3(2):77-93
pubmed: 12678904
Nature. 2004 Sep 23;431(7007):461-6
pubmed: 15329734
World J Gastroenterol. 2004 Oct 15;10(20):3048-52
pubmed: 15378791
Cancer Cell. 2004 Sep;6(3):203-8
pubmed: 15380510
J Korean Med Sci. 2004 Oct;19(5):710-5
pubmed: 15483349
Immunol Rev. 2004 Dec;202:49-66
pubmed: 15546385
J Immunol. 2005 Jan 1;174(1):21-5
pubmed: 15611222
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
J Cell Biol. 2006 Mar 27;172(7):973-81
pubmed: 16567498
Biochem Pharmacol. 2006 Nov 30;72(11):1605-21
pubmed: 16889756
Cancer Metastasis Rev. 2006 Sep;25(3):409-16
pubmed: 16951987
Nature. 2007 Nov 29;450(7170):712-6
pubmed: 18046409
Curr Protoc Mol Biol. 2001 May;Chapter 10:Unit 10.16
pubmed: 18265056
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Nat Rev Cancer. 2009 Apr;9(4):265-73
pubmed: 19262571
Nat Rev Cancer. 2009 May;9(5):361-71
pubmed: 19343034
Br J Pharmacol. 2009 Jun;157(3):436-50
pubmed: 19371341
Clin Cancer Res. 2009 May 15;15(10):3557-67
pubmed: 19447876
J Cell Mol Med. 2009 Jul;13(7):1314-20
pubmed: 19604316
Immunobiology. 2009;214(9-10):761-77
pubmed: 19616341
Future Oncol. 2009 Oct;5(8):1129-43
pubmed: 19852726
Br J Cancer. 2010 Feb 16;102(4):639-44
pubmed: 20087353
Basic Clin Pharmacol Toxicol. 2010 Aug;107(2):650-5
pubmed: 20406206
BMC Cancer. 2011 Apr 12;11:130
pubmed: 21486440
Proteome Sci. 2011 Aug 17;9(1):49
pubmed: 21849056
Biosci Rep. 2012 Feb;32(1):1-15
pubmed: 21981137
Cancer Res. 2012 Mar 1;72(5):1290-300
pubmed: 22253230
Mol Cancer Res. 2012 Aug;10(8):1109-19
pubmed: 22707636
Oral Oncol. 2012 Nov;48(11):1068-75
pubmed: 22766510
Cancer Res. 2013 Apr 15;73(8):2418-27
pubmed: 23436798
J Pathol. 2014 Jan;232(1):43-56
pubmed: 24014111
Biochem Biophys Res Commun. 2013 Nov 29;441(4):891-6
pubmed: 24211585
Hybridoma. 1987 Oct;6(5):489-507
pubmed: 2445655
Mol Nutr Food Res. 2014 Jul;58(7):1389-401
pubmed: 24659233
J Immunol Res. 2014;2014:149185
pubmed: 24901008
J Biol Chem. 2014 Aug 8;289(32):22048-62
pubmed: 24962570
Semin Cell Dev Biol. 2014 Dec;36:224-31
pubmed: 25239399
J Cancer Res Clin Oncol. 2015 Oct;141(10):1697-713
pubmed: 25270087
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
BMC Cancer. 2015 Apr 10;15:250
pubmed: 25884903
Am J Cancer Res. 2015 Apr 15;5(5):1680-91
pubmed: 26175937
Biochem Pharmacol. 2015 Nov 1;98(1):51-68
pubmed: 26310874
Acta Pharm Sin B. 2014 Jun;4(3):173-81
pubmed: 26579381
Exp Ther Med. 2015 Nov;10(5):1725-1731
pubmed: 26640543
Nutrients. 2016 Mar 05;8(3):145
pubmed: 26959057
Cell Physiol Biochem. 2016;39(6):2203-2215
pubmed: 27832627
Cold Spring Harb Symp Quant Biol. 2016;81:11-19
pubmed: 28057845
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Med Oncol. 2017 Jul;34(7):122
pubmed: 28560682
Semin Cancer Biol. 2017 Oct;46:158-181
pubmed: 28823533
Nutrients. 2017 Sep 27;9(10):null
pubmed: 28953264
Nutrients. 2018 Jul 12;10(7):null
pubmed: 30002278
Mol Med. 2018 Jun 5;24(1):29
pubmed: 30134816
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Semin Cancer Biol. 2018 Nov 22;:null
pubmed: 30472212
Int J Cancer. 2019 Jun 15;144(12):2992-3000
pubmed: 30536395
Exp Biol Med (Maywood). 2019 Jan;244(1):1-12
pubmed: 30661394
J Biol Chem. 1996 Oct 4;271(40):24934-8
pubmed: 8798772
Cell Biol Int. 1997 Feb;21(2):75-86
pubmed: 9080655
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2460-5
pubmed: 9122217
Int J Biochem Cell Biol. 1997 Dec;29(12):1433-48
pubmed: 9570137
Front Biosci. 1999 Jan 15;4:D102-13
pubmed: 9889179

Auteurs

Constanze Buhrmann (C)

Musculoskeletal Research Group and Tumor Biology, Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilian-University Munich, Pettenkoferstrasse 11, D-80336 Munich, Germany. constanze.buhrmann@med.uni-muenchen.de.

Mina Yazdi (M)

Musculoskeletal Research Group and Tumor Biology, Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilian-University Munich, Pettenkoferstrasse 11, D-80336 Munich, Germany. Mina.Yazdi@med.uni-muenchen.de.

Bastian Popper (B)

Biomedical Center, Core Facility Animal Models, Ludwig-Maximilian-University Munich, D-82152 Martinsried, Germany. Bastian.Popper@bmc.med.lmu.de.

Ajaikumar B Kunnumakkara (AB)

Cancer Biology Laboratory & DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), Department of Biosciences & Bioengineering, Indian Institute of Technology Guwahati, Assam 781039, India. ajai78@gmail.com.

Bharat B Aggarwal (BB)

Anti-inflammation Research Institute, San Diego, CA 92126, USA. bbaggarwal@gmail.com.

Mehdi Shakibaei (M)

Musculoskeletal Research Group and Tumor Biology, Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilian-University Munich, Pettenkoferstrasse 11, D-80336 Munich, Germany. mehdi.shakibaei@med.uni-muenchen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH